John J. Treanor, MD; H. Reid Mattison, MD; Ghinwa Dumyati, MD; Amos Yinnon, MD; Shirley Erb, RN; Diane O'Brien, RN; Raphael Dolin, MD; Robert F. Betts, MD
Treanor J., Mattison H., Dumyati G., Yinnon A., Erb S., O'Brien D., Dolin R., Betts R.; Protective Efficacy of Combined Live Intranasal and Inactivated Influenza A Virus Vaccines in the Elderly. Ann Intern Med. 1992;117:625-633. doi: 10.7326/0003-4819-117-8-625
Download citation file:
Published: Ann Intern Med. 1992;117(8):625-633.
▪ Objective: To evaluate the efficacy of adding intranasal live attenuated cold-adapted influenza A vaccine to inactivated influenza vaccine to prevent influenza A in elderly residents of long-term-care institutions.
▪ Design: Randomized, double-blind, placebo-controlled study conducted over 3 years.
▪ Setting: Three large nursing homes.
▪ Participants: A total of 523 residents of nursing homes (mean age, 84.2 years).
▪ Interventions: All participants received trivalent inactivated influenza vaccine parenterally and were randomly assigned to receive either live attenuated influenza A (H3N2) virus vaccine or placebo intranasally.
▪ Measurements: Laboratory-documented influenza A was defined as a respiratory illness plus isolation of influenza A virus from nasal secretions, significant serologic response, or both. Participants were considered to have been exposed to influenza A if they resided in an institution in which cases of influenza A were documented. Outbreak-associated illnesses were defined as those occurring between the first and last isolation of influenza virus from within the institution, ± 3 days.
▪ Results: Participants who received intranasal vaccine and were subsequently exposed to influenza A had significantly lower rates of laboratory-documented influenza A (9 of 162 vaccine recipients compared with 24 of 169 placebo recipients; vaccine protective efficacy, 60.6%; 95% Cl, 18% to 82%), outbreak-associated respiratory illnesses (13 of 162 vaccine recipients compared with 34 of 169 placebo recipients; vaccine protective efficacy, 56.8%; Cl 23% to 76%), and outbreakassociated influenza-like illnesses (6 of 162 vaccine recipients compared with 18 of 169 placebo recipients; vaccine protective efficacy, 65.0%; Cl 17% to 86%).
▪ Conclusions: Intranasal immunization with live attenuated influenza A virus vaccine provided additional protection against influenza A when added to parenteral trivalent inactivated influenza vaccine among elderly nursing home residents.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Geriatric Medicine, Infectious Disease, Vaccines/Immunization, Influenza, Prevention/Screening.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only